

QIBA fMRI Biomarker Committee (BC) Call

Wednesday, April 17, 2019 at 11 AM CT

Call Summary

In attendance

Jay Pillai, MD (Co-chair)

David Soltysik, PhD (Co-chair)

Shruti Agarwal, PhD

Cathy Elsinger, PhD

Andrew Kalnin, MD

Ho-Ling (Anthony) Liu, PhD

Nancy Obuchowski, PhD

Yuxiang Zhou, PhD

RSNA staff

Joe Koudelik

Susan Stanfa

Moderator: Dr. Soltysik

Review of Previous Call Summary

- The 04.03.2019 call summary was approved as presented

Upcoming fMRI Bias TF T-cons

- There will be not be fMRI Bias TF meetings on Tuesday, April 23 or May 14
- The group will reconvene on Tuesday, May 28

Potential fMRI BC Groundwork Project

- The Sustainability Implementation Group (SIG) requested that all QIBA CCs provide up to three groundwork projects that would help advance the current Profiles, by April 15th.
- Dr. Elsinger submitted the fMRI project description to MR CC Co-Chairs on April 10; the topic was quantitative aspects of Resting State fMRI (rs-fMRI), assessment of its reproducibility as a potential biomarker, and how it may be applied to neurodegenerative disease and clinical trials
- To date, nine other projects had been submitted across all four QIBA modalities
- The remainder of the discussion focused on investigating potential pharma-related entities to target and potential users of the fMRI Profile
 - Clinical trials for Alzheimer's drugs may benefit from the work of the fMRI BC
 - Clinicaltrials.gov was referenced during the t-con to see which companies were already using rs-fMRI
 - Pfizer was cited as a company with a history of using fMRI in clinical trials and it may be a good place to start
 - Different search strategies were employed and results were reviewed for each
 - Results can be limited by "Industry" funders
 - Trials can be searched with the key phrase, "resting state"
 - There was brief discussion regarding one particular study on chronic pain:
<https://clinicaltrials.gov/ct2/show/NCT02987933?cond=resting+state&fund=2&rank=1>
 - Dr. Elsinger to follow up with Dr. Zahlmann re ongoing studies using rs-fMRI and possible contacts
- It was noted that studies using neuroimaging may not be directly connected to pharma companies, as they are usually funded by NIH and conducted in collaboration with other types of companies
- It was noted that due to the short turnaround time and no guarantee of funding, project descriptions were not distributed across BC email rosters for feedback
 - The document was submitted to MR CC Co-Chairs, to be discussed during the April 24 MR CC quarterly meeting

- Should one of the pharma companies be interested in providing funding, a full study design would be needed and fMRI BC members would be given a chance to provide feedback

fMRI Profile v2.0: Language-Mapping

- This item was tabled until the May 1 fMRI BC call, during which Claims and the status on the literature search for the fMRI Language-mapping Profile v2.0 will be discussed
- Existing literature may need to be revisited to determine whether there are new reproducibility studies for discussion

Next calls:

- QIBA fMRI Biomarker Cmte call – **Wednesday, May 1, 2019** at 11am CT - 1st & 3rd weeks of the month
- QIBA fMRI Bias TF call – **Tuesday, May 28, 2019** at 1 PM CT - 2nd & 4th weeks of the month

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, **if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible.** Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries.